Use should be avoided.

AU TGA pregnancy category: B3
US FDA pregnancy category: C

Animal studies using dermal application do not indicate direct or indirect harmful effects with respect to embryofetal development. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Based on the minimal extent of absorption of this drug after topical application, the potential risk for humans is considered limited. Breastfeeding mothers should not apply this drug to the breast because ointments may expose the infant to high levels of mineral paraffin via licking.

AU, US: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
UK: Use is considered acceptable.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

See references